Loading clinical trials...

Schizophrenic Patients in Integrated Care | Clinical Trials | Clareo Health

TERMINATEDPHASE4

Schizophrenic Patients in Integrated Care

CARE II - Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-country, Multi-centre Phase IV Study

NCT00681629•AstraZeneca

View on ClinicalTrials.gov

Summary

The purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine XR combined with participation in the integrated care program compared to a treatment with quetiapine XR alone over a period of 18 month

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with baseline SWN-K \<=70
•Provision of signed informed consent
•Out-patients with schizophrenia, schizophreniform disorder or schizoaffective disorder, severe postpartum depressive disorders with psychotic symptoms and a minimum HAM-D cut off score of 20 points

Exclusion Criteria

•Evidence of a clinical relevant disease, eg renal or hepatic impairment, significant coronary heart disease, hepatitis B or C, AIDS
•Patients with known cardiovascular disease or other condition predisposing to hypotension or family history of QT prolongation
•Patients who pose an imminent risk of suicide or danger to self or others

Locations (8)

Research Site

München, Bavaria, Germany

Research Site

Oranienburg, Brandenburg, Germany

Research Site

Hamburg, Hamburg, Germany

Research Site

Lüneburg, Lower Saxony, Germany

Research Site

Oldenburg, Lower Saxony, Germany

Research Site

Chemnitz, Saxony, Germany

Research Site

Berlin, State of Berlin, Germany

Research Site

Stolberg, Germany

Key Dates

Start Date

July 1, 2008

Primary Completion Date

November 1, 2008

Completion Date

November 1, 2008

Last Updated

July 30, 2012

Enrollment

ACTUAL participants

Conditions

SchizophreniaSchizoaffective DisorderSchizophreniform Disorder

Interventions

Quetiapine XR

DRUG

Integrated Care Program (ICP)

OTHER

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 30, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Schizophrenic Patients in Integrated Care

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques

Brain Stimulation to the Hippocampus in Schizophrenia